High-dose cyclophosphamide administered after peripheral blood stem cell (PBSC) transplantation can reduce the risk of chronic graft-versus-host disease (GVHD), according to a single-center study of 43 patients. Median age of the patients was 43 years, and 12 (28%) received grafts from related donors and 31 (72%) received grafts from unrelated donors. Cyclophosphamide was given at 50 mg/kg of patient weight per day on days 3 and 4 after transplantation, followed by cyclosporine starting on day 5. The cumulative 1-year incidence of chronic GVHD was 16%, which the authors note is substantially lower than the approximately 35% rate of 1-year chronic GVHD reported historically after PBSC transplantation.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Reduced Risk of Chronic GVHD with Post-Transplant Cyclophosphamide
Apr 2016